IMARC Group’s report titled “Human Chorionic Gonadotropin (HCG) Market Report by Technology (Natural Source Extraction, Recombinant Technology), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermic Treatment, and Others), End User (Fertility Clinics, Research Institutions, and Others), and Region 2024-2032“, offers a comprehensive analysis of the industry, which comprises insights on the global human chorionic gonadotropin (HCG) market demand. The global market size reached US$ 973.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,768.4 Million by 2032, exhibiting a growth rate (CAGR) of 6.65% during 2024-2032.
For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/human-chorionic-gonadotropin-market/requestsample
Factors Affecting the Growth of the Human Chorionic Gonadotropin (HCG) Industry:
- Rising Prevalence of Infertility:
The increasing rates of infertility among individuals on account of delayed childbearing, lifestyle changes, and environmental factors are contributing to the growth of the market. HCG injections are pivotal in fertility treatments, stimulating ovulation in women and enhancing sperm production in men. HCG offers medications and therapies that benefit in supporting reproductive health. In addition, the escalating demand for assisted reproductive technologies (ART) like HCG-based interventions due to conceiving challenges faced by individuals or couples is propelling the market growth.
- Increasing Awareness and Acceptance of Assisted Reproductive Technologies (ART):
The rising awareness and acceptance of ART procedures, such as in vitro fertilization (IVF) and intrauterine insemination (IUI), is bolstering the market growth. Individuals are opting for fertility treatments to overcome infertility challenges and achieve pregnancy. The growing understanding about the effectiveness and success rate of ART, coupled with advancements in reproductive medicine, is offering a positive market outlook. Moreover, governing agencies of various countries are organizing campaigns to generate awareness about infertility treatments, which is propelling the market growth.
- Technological Advancements in Healthcare:
Technological advancements in healthcare, particularly in the field of reproductive medicine, are impelling the market growth. Innovations in ART, such as improved embryo culture techniques, genetic screening methods, and precision medicine approaches, are leading to higher success rates in fertility treatments. In addition, the integration of advanced technologies not only enhances the efficacy of fertility treatments but also improves patient outcomes, encouraging confidence and trust among individuals in these interventions. Innovative delivery methods, such as subcutaneous injections and nasal sprays, enhance convenience and patient compliance.
Leading Companies Operating in the Global Human Chorionic Gonadotropin Industry:
- Biocare Medical LLC
- Ferring Pharmaceuticals
- Fresenius SE & Co. KGaA
- Kamiya Biomedical Company (Nitto Boseki Co. Ltd.)
- Lee Biosolutions Inc. (Oy Medix Biochemica Ab)
- Merck & Co. Inc.
- Prospec-Tany Technogene Ltd.
- Scripps Laboratories Inc.
- Sun Pharmaceutical Industries Limited
Human Chorionic Gonadotropin (HCG) Market Report Segmentation:
By Technology:
- Natural Source Extraction
- Recombinant Technology
Natural source extraction represents the largest segment as it ensures high potency and purity of the final product.
By Therapeutic Area:
- Female Infertility Treatment
- Male Hypogonadism
- Oligospermic Treatment
- Others
Female infertility treatment holds the biggest market share on account of the rising prevalence of conditions, such as ovulatory disorders, polycystic ovary syndrome (PCOS), and age-related infertility among women.
By End User:
- Fertility Clinics
- Research Institutions
- Others
Fertility clinics account for the largest market share due to the increasing need for specialized services among individuals.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America enjoys a leading position in the human chorionic gonadotropin (HCG) market, which can be attributed to the presence of advanced healthcare infrastructure.
Global Human Chorionic Gonadotropin (HCG) Market Trends:
The growing demand for HCG on account of the rising number of age-related infertility cases among individuals across the globe is offering a positive market outlook. Older couples are increasingly adopting HCG-based interventions to fulfill their desire for parenthood. Apart from this, the increasing adoption of HCG due to the thriving medical tourism, particularly for fertility treatments, is impelling the market growth. People are preferring advanced healthcare facilities with affordable treatment options.
In line with this, people are increasingly facing infertility issues due to various factors, such as sedentary lifestyles, stress, pollution, and dietary habits, which are propelling the market growth.
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
